In a report released yesterday, Mark Massaro from Canaccord Genuity reiterated a Hold rating on Meridian Bioscience Inc (VIVO), with a price target of $17. The company’s shares opened today at $16.51.
According to TipRanks.com, Massaro is a 5-star analyst with an average return of 14.2% and a 56.2% success rate. Massaro covers the Healthcare sector, focusing on stocks such as HTG Molecular Diagnostics, Quanterix Corporation, and Orasure Technologies.
Currently, the analyst consensus on Meridian Bioscience Inc is a Moderate Sell with an average price target of $17.
See today’s analyst top recommended stocks >>
Meridian Bioscience Inc’s market cap is currently $706.4M and has a P/E ratio of 27.91. The company has a Price to Book ratio of 4.03.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is neutral on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Meridian Bioscience, Inc. engages in the development, manufacture, sale, and distribution of diagnostic test kits, antigens, reagents, and related products. It operates through the Diagnostics and Life Science segment.
